nach oben

Current Treatment Options in Neurology

Erschienen in:

01.01.2019 | Sleep Disorders (A Iranzo, Section Editor)

Sleep Abnormalities in Multiple Sclerosis

verfasst von: Giorgos K. Sakkas, PhD, Christoforos D. Giannaki, PhD, Christina Karatzaferi, PhD, Mauro Manconi, MD, PhD

Erschienen in: Current Treatment Options in Neurology | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose of review

This review summarizes the most well-documented sleep disorders seen in patients with multiple sclerosis (MS), with a special focus on the impact on quality of life.

Recent findings

Sleep abnormalities in patients with MS are a multifactorial and relatively complex issue affecting approximately 60% of the patients while the pathophysiology of these symptoms is not fully understood. Circadian rhythm disorders and increased levels of pro-inflammatory cytokines have been recognized as potential players in affecting sleep homeostasis in MS patients. Medication-related side effects such as in immunotherapy and other factors such as lesion load can contribute to the disruption of normal sleep patterns.

Summary

Most frequently encountered sleep disorders are insomnia, sleep-related movement disorders, sleep-related breathing disorders, and circadian rhythm disorders affecting both adults and paediatric MS populations. Aetiology still remains unknown with treatment options focusing on behavioural cognitive therapy and lifestyle modification including improvement in sleep hygiene as well as melatonin supplementation. Given MS prevalence is still rising affecting millions of people, more personalized medicine applications should possibly form the key approach for improving patients’ quality of life and quality years.

Buysse DJ. Sleep health: can we define it? Does it matter? Sleep. 2014;37(1):9–17. https://doi.org/10.5665/sleep.3298.PubMedPubMedCentralCrossRef

Cavalera C, Rovaris M, Mendozzi L, Pugnetti L, Garegnani M, Castelnuovo G, et al. Online meditation training for people with multiple sclerosis: a randomized controlled trial. Mult Scler. 2018;1352458518761187:135245851876118. https://doi.org/10.1177/1352458518761187.CrossRef

Hughes AJ, Dunn KM, Chaffee T. Sleep disturbance and cognitive dysfunction in multiple sclerosis: a systematic review. Curr Neurol Neurosci Rep. 2018;18(1):2. https://doi.org/10.1007/s11910-018-0809-7.PubMedCrossRef

Vitkova M, Gdovinova Z, Rosenberger J, Szilasiova J, Nagyova I, Mikula P, et al. Factors associated with poor sleep quality in patients with multiple sclerosis differ by disease duration. Disabil Health J. 2014;7(4):466–71. https://doi.org/10.1016/j.dhjo.2014.05.004.PubMedCrossRef

Archer SN, Laing EE, Moller-Levet CS, van der Veen DR, Bucca G, Lazar AS, et al. Mistimed sleep disrupts circadian regulation of the human transcriptome. Proc Natl Acad Sci U S A. 2014;111(6):E682–91. https://doi.org/10.1073/pnas.1316335111.PubMedPubMedCentralCrossRef

Calandra-Buonaura G, Provini F, Guaraldi P, Plazzi G, Cortelli P. Cardiovascular autonomic dysfunctions and sleep disorders. Sleep Med Rev. 2016;26:43–56. https://doi.org/10.1016/j.smrv.2015.05.005.PubMedCrossRef

Harbo HF, Gold R, Tintore M. Sex and gender issues in multiple sclerosis. Ther Adv Neurol Disord. 2013;6(4):237–48. https://doi.org/10.1177/1756285613488434.PubMedPubMedCentralCrossRef

Gilmour H, Ramage-Morin PL, Wong SL. Multiple sclerosis: prevalence and impact. Health Rep. 2018;29(1):3–8.PubMed

Browne P, Chandraratna D, Angood C, Tremlett H, Baker C, Taylor BV, et al. Atlas of multiple sclerosis 2013: a growing global problem with widespread inequity. Neurology. 2014;83(11):1022–4. https://doi.org/10.1212/WNL.0000000000000768.PubMedPubMedCentralCrossRef

10.

Matveeva O, Bogie JFJ, Hendriks JJA, Linker RA, Haghikia A, Kleinewietfeld M. Western lifestyle and immunopathology of multiple sclerosis. Ann N Y Acad Sci. 2018;1417(1):71–86. https://doi.org/10.1111/nyas.13583.PubMedPubMedCentralCrossRef

11.

Belbasis L, Bellou V, Evangelou E, Ioannidis JP, Tzoulaki I. Environmental risk factors and multiple sclerosis: an umbrella review of systematic reviews and meta-analyses. Lancet Neurol. 2015;14(3):263–73. https://doi.org/10.1016/S1474-4422(14)70267-4.PubMedCrossRef

12.

Olsson T, Barcellos LF, Alfredsson L. Interactions between genetic, lifestyle and environmental risk factors for multiple sclerosis. Nat Rev Neurol. 2017;13(1):25–36. https://doi.org/10.1038/nrneurol.2016.187.PubMedCrossRef

13.

Kaynak H, Altintas A, Kaynak D, Uyanik O, Saip S, Agaoglu J, et al. Fatigue and sleep disturbance in multiple sclerosis. Eur J Neurol. 2006;13(12):1333–9. https://doi.org/10.1111/j.1468-1331.2006.01499.x.PubMedCrossRef

14.

• Amtmann D, Bamer AM, Kim J, Chung H, Salem R. People with multiple sclerosis report significantly worse symptoms and health related quality of life than the US general population as measured by PROMIS and NeuroQoL outcome measures. Disabil Health J. 2018;11(1):99–107. https://doi.org/10.1016/j.dhjo.2017.04.008 Individuals with MS report clinically meaningful worse health compared to the general population across multiple health related domains. Symptom profiles utilizing PROMIS or NeuroQoL measures can be used to quickly assess symptom levels in an individual or group.PubMedCrossRef

15.

Shahrbanian S, Duquette P, Kuspinar A, Mayo NE. Contribution of symptom clusters to multiple sclerosis consequences. Qual Life Res. 2015;24(3):617–29. https://doi.org/10.1007/s11136-014-0804-7.PubMedCrossRef

16.

Bamer AM, Johnson KL, Amtmann D, Kraft GH. Prevalence of sleep problems in individuals with multiple sclerosis. Mult Scler. 2008;14(8):1127–30. https://doi.org/10.1177/1352458508092807.PubMedPubMedCentralCrossRef

17.

• Garland SN, Scurrey SRM, Ploughman M, Health L, Aging with MSCC. Factors associated with poor sleep in older adults with multiple sclerosis. Int J Behav Med. 2017;24(6):937–45. https://doi.org/10.1007/s12529-017-9653-4 Individuals with MS who had clinically significant levels of anxiety were two times more likely to have trouble sleeping when compared to individuals without anxiety. Efforts should focus on early identification and effective interventions for poor sleep in individuals living with MS.PubMedCrossRef

18.

Boe Lunde HM, Aae TF, Indrevag W, Aarseth J, Bjorvatn B, Myhr KM, et al. Poor sleep in patients with multiple sclerosis. PLoS One. 2012;7(11):e49996. https://doi.org/10.1371/journal.pone.0049996.PubMedPubMedCentralCrossRef

19.

•• Morris G, Stubbs B, Kohler CA, Walder K, Slyepchenko A, Berk M, et al. The putative role of oxidative stress and inflammation in the pathophysiology of sleep dysfunction across neuropsychiatric disorders: Focus on chronic fatigue syndrome, bipolar disorder and multiple sclerosis. Sleep Med Rev. 2018. https://doi.org/10.1016/j.smrv.2018.03.007 This review focus on chronic fatigue syndrome, bipolar disorder, and multiple sclerosis as exemplars of neuro-immune disorders. They concluded that novel therapeutic targets exploring immune and oxidative & nitrosative pathways (p.e. melatonin and molecular hydrogen) hold promise in alleviating sleep and circadian dysfunction in these disorders.PubMedCrossRef

20.

Schutte-Rodin S, Broch L, Buysse D, Dorsey C, Sateia M. Clinical guideline for the evaluation and management of chronic insomnia in adults. J Clin Sleep Med. 2008;4(5):487–504.PubMedPubMedCentral

21.

Chalah MA, Riachi N, Ahdab R, Creange A, Lefaucheur JP, Ayache SS. Fatigue in multiple sclerosis: neural correlates and the role of non-invasive brain stimulation. Front Cell Neurosci. 2015;9:460. https://doi.org/10.3389/fncel.2015.00460.PubMedPubMedCentralCrossRef

22.

Veauthier C, Radbruch H, Gaede G, Pfueller CF, Dorr J, Bellmann-Strobl J, et al. Fatigue in multiple sclerosis is closely related to sleep disorders: a polysomnographic cross-sectional study. Mult Scler. 2011;17(5):613–22. https://doi.org/10.1177/1352458510393772.PubMedCrossRef

23.

Bamer AM, Johnson KL, Amtmann DA, Kraft GH. Beyond fatigue: assessing variables associated with sleep problems and use of sleep medications in multiple sclerosis. Clin Epidemiol. 2010;2010(2):99–106. https://doi.org/10.2147/CLEP.S10425.PubMedCrossRef

24.

Merlino G, Fratticci L, Lenchig C, Valente M, Cargnelutti D, Picello M, et al. Prevalence of ‘poor sleep’ among patients with multiple sclerosis: an independent predictor of mental and physical status. Sleep Med. 2009;10(1):26–34. https://doi.org/10.1016/j.sleep.2007.11.004.PubMedCrossRef

25.

Neau JP, Paquereau J, Auche V, Mathis S, Godeneche G, Ciron J, et al. Sleep disorders and multiple sclerosis: a clinical and polysomnography study. Eur Neurol. 2012;68(1):8–15. https://doi.org/10.1159/000335076.PubMedCrossRef

26.

•• Group GBDNDC. Global, regional, and national burden of neurological disorders during 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Neurol. 2017;16(11):877–97. https://doi.org/10.1016/S1474-4422(17)30299-5 This systematic analysis assess the global burden of neurological disorders. They concluded that the number has increased substantially over the past 25 years because of expanding population numbers and ageing, despite substantial decreases in mortality rates from stroke and communicable neurological disorders. The number of patients who will need care by clinicians with expertise in neurological conditions will continue to grow in coming decades. Policy makers and health-care providers should be aware of these trends to provide adequate services. CrossRef

27.

Wade BJ. Spatial analysis of global prevalence of multiple sclerosis suggests need for an updated prevalence scale. Mult Scler Int. 2014;2014:124578–7. https://doi.org/10.1155/2014/124578.PubMedPubMedCentralCrossRef

28.

Melcon MO, Correale J, Melcon CM. Is it time for a new global classification of multiple sclerosis? J Neurol Sci. 2014;344(1–2):171–81. https://doi.org/10.1016/j.jns.2014.06.051.PubMedCrossRef

29.

Ebers GC. Environmental factors and multiple sclerosis. Lancet Neurol. 2008;7(3):268–77. https://doi.org/10.1016/S1474-4422(08)70042-5.PubMedCrossRef

30.

Wendel-Haga M, Celius EG. Is the hygiene hypothesis relevant for the risk of multiple sclerosis? Acta Neurol Scand. 2017;136(Suppl 201):26–30. https://doi.org/10.1111/ane.12844.PubMedCrossRef

31.

Brass SD, Li CS, Auerbach S. The underdiagnosis of sleep disorders in patients with multiple sclerosis. J Clin Sleep Med. 2014;10(9):1025–31. https://doi.org/10.5664/jcsm.4044.PubMedPubMedCentralCrossRef

32.

Manconi M, Fabbrini M, Bonanni E, Filippi M, Rocca M, Murri L, et al. High prevalence of restless legs syndrome in multiple sclerosis. Eur J Neurol. 2007;14(5):534–9.PubMedCrossRef

33.

Manconi M, Ferini-Strambi L, Filippi M, Bonanni E, Iudice A, Murri L, et al. Multicenter case-control study on restless legs syndrome in multiple sclerosis: the REMS study. Sleep. 2008;31(7):944–52.PubMedPubMedCentralCrossRef

34.

Douay X, Waucquier N, Hautecoeur P, Vermersch P. G SEP. (high prevalence of restless legs syndrome in multiple sclerosis). Rev Neurol. 2009;165(2):194–6. https://doi.org/10.1016/j.neurol.2008.06.001.PubMedCrossRef

35.

Vavrova J, Kemlink D, Sonka K, Havrdova E, Horakova D, Pardini B, et al. Restless legs syndrome in Czech patients with multiple sclerosis: an epidemiological and genetic study. Sleep Med. 2012;13(7):848–51. https://doi.org/10.1016/j.sleep.2012.03.012.PubMedCrossRef

36.

•• Braley TJ, Chervin RD. A practical approach to the diagnosis and management of sleep disorders in patients with multiple sclerosis. Ther Adv Neurol Disord. 2015;8(6):294–310. https://doi.org/10.1177/1756285615605698 This is a very important review. It summarizes the most common sleep disorders experienced by persons with MS, and offers a practical approach to diagnosis and management of these conditions.PubMedPubMedCentralCrossRef

37.

•• Veauthier C, Paul F. Sleep disorders in multiple sclerosis and their relationship to fatigue. Sleep Med. 2014;15(1):5–14. https://doi.org/10.1016/j.sleep.2013.08.791 This review assess the impact of sleep disorders in relation to fatigue in patients with MS. The authors suggest that an effective treatment of sleep disorders can lead to an improvement of MS-related fatigue and they propose that in all MS studies, researchers should investigate sleep and considere it as a relevant confounder.PubMedCrossRef

38.

Stanton BR, Barnes F, Silber E. Sleep and fatigue in multiple sclerosis. Mult Scler. 2006;12(4):481–6. https://doi.org/10.1191/135248506ms1320oa.PubMedCrossRef

39.

• Alhazzani AA, Alshahrani A, Alqahtani M, Alamri R, Alqahtani R, Alqahtani M, et al. Insomnia among non-depressed multiple sclerosis patients: a cross-sectional study. Egypt J Neurol Psychiatr Neurosurg. 2018;54(1):17. https://doi.org/10.1186/s41983-018-0016-0 The study was conducted to assess insomnia among non-depressed MS patients in Saudi Arabia. Prevalence of insomnia among non-depressed MS patients is low while it is associated with educational and use of antidepressants.PubMedPubMedCentralCrossRef

40.

Espie CA, Luik AI, Cape J, Drake CL, Siriwardena AN, Ong JC, et al. Digital Cognitive Behavioural Therapy for Insomnia versus sleep hygiene education: the impact of improved sleep on functional health, quality of life and psychological well-being. Study protocol for a randomised controlled trial. Trials. 2016;17(1):257. https://doi.org/10.1186/s13063-016-1364-7.PubMedPubMedCentralCrossRef

41.

•• Morin CM, Beaulieu-Bonneau S, Belanger L, Ivers H, Sanchez Ortuno M, Vallieres A, et al. Cognitive-behavior therapy singly and combined with medication for persistent insomnia: Impact on psychological and daytime functioning. Behav Res Ther. 2016;87:109–16. https://doi.org/10.1016/j.brat.2016.09.002 The study evaluated the impact of cognitive-behavior therapy alone and combined with medication, on various indices of daytime and psychological functioning. Following acute treatment, significant improvements of fatigue, quality of life (mental component), anxiety, and depression were obtained in the CBT alone condition but not in the combined CBT plus medication condition. Following extended treatment, further improvements were noted for the subgroup receiving extended CBT relative to that with no additional treatment, and for the subgroup receiving CBT and intermittent medication relative to that with CBT but no medication.PubMedPubMedCentralCrossRef

42.

• Sanchez-Barcelo EJ, Rueda N, Mediavilla MD, Martinez-Cue C, Reiter RJ. Clinical Uses of Melatonin in Neurological Diseases and Mental and Behavioural Disorders. Curr Med Chem. 2017;24(35):3851–78. https://doi.org/10.2174/0929867324666170718105557 In this review article, the administration of melatonin to humans for various therapeutic purposes in the field of neuropathology was assessed. The authors concluded that melatonin has the potential to become a strong player in the improvement of sleep in patients with neurological disorders, however clinical trials with strong methodologies and appropriate doses of melatonin are necessary to further support the usefulness of melatonin.PubMedCrossRef

43.

Becker PM, Sharon D. Mood disorders in restless legs syndrome (Willis-Ekbom disease). J Clin Psychiatry. 2014;75(7):e679–94. https://doi.org/10.4088/JCP.13r08692.PubMedCrossRef

44.

Allen RP, Picchietti DL, Garcia-Borreguero D, Ondo WG, Walters AS, Winkelman JW, et al. Restless legs syndrome/Willis-Ekbom disease diagnostic criteria: updated International Restless Legs Syndrome Study Group (IRLSSG) consensus criteria--history, rationale, description, and significance. Sleep Med. 2014;15(8):860–73. https://doi.org/10.1016/j.sleep.2014.03.025.PubMedCrossRef

45.

Hardy De Buisseret FX, Mairesse O, Newell J, Verbanck P, Neu D. While isolated periodic limb movement disorder significantly impacts sleep depth and efficiency, co-morbid restless leg syndrome mainly exacerbates perceived sleep quality. Eur Neurol. 2017;77(5–6):272–80. https://doi.org/10.1159/000471920.PubMedCrossRef

46.

Gomez-Choco MJ, Iranzo A, Blanco Y, Graus F, Santamaria J, Saiz A. Prevalence of restless legs syndrome and REM sleep behavior disorder in multiple sclerosis. Mult Scler. 2007;13(6):805–8. https://doi.org/10.1177/1352458506074644.PubMedCrossRef

47.

Giannaki CD, Hadjigeorgiou GM, Karatzaferi C, Pantzaris MC, Stefanidis I, Sakkas GK. Epidemiology, impact, and treatment options of restless legs syndrome in end-stage renal disease patients: an evidence-based review. Kidney Int. 2014;85(6):1275–82. https://doi.org/10.1038/ki.2013.394.PubMedCrossRef

48.

Manconi M, Ferri R, Feroah TR, Zucconi M, Ferini-Strambi L. Defining the boundaries of the response of sleep leg movements to a single dose of dopamine agonist. Sleep. 2008;31(9):1229–37.PubMedPubMedCentral

49.

Minar M, Petrlenicova D, Valkovic P. Higher prevalence of restless legs syndrome/Willis-Ekbom disease in multiple sclerosis patients is related to spinal cord lesions. Mult Scler Relat Disord. 2017;12:54–8. https://doi.org/10.1016/j.msard.2016.12.013.PubMedCrossRef

50.

Manconi M, Rocca MA, Ferini-Strambi L, Tortorella P, Agosta F, Comi G, et al. Restless legs syndrome is a common finding in multiple sclerosis and correlates with cervical cord damage. Mult Scler. 2008;14(1):86–93. https://doi.org/10.1177/1352458507080734.PubMedCrossRef

51.

•• Giannaki CD, Aristotelous P, Stefanakis M, Hadjigeorgiou GM, Manconi M, Leonidou E, et al. Restless legs syndrome in Multiple Sclerosis patients: a contributing factor for fatigue, impaired functional capacity, and diminished health-related quality of life. Neurol Res. 2018;40(7):586–92. https://doi.org/10.1080/01616412.2018.1454719 The study was assessing whether RLS could affect the functional capacity and various contributing parameters related to quality of life and fatigue in MS patients. The aurthors concluded that RLS seems to contribute even further to impairments on sleep, fatigue, functional capacity, and therefore HRQoL levels in relapsing-remitting MS patients.PubMedCrossRef

52.

•• Kotterba S, Neusser T, Norenberg C, Bussfeld P, Glaser T, Dorner M, et al. Sleep quality, daytime sleepiness, fatigue, and quality of life in patients with multiple sclerosis treated with interferon beta-1b: results from a prospective observational cohort study. BMC Neurol. 2018;18(1):123. https://doi.org/10.1186/s12883-018-1113-5 This observational cohort study was aiming to investigate the relationship between sleep quality, fatigue, quality of life, and comorbidities in patients with MS. The authors confirm the high prevalence of poor sleep quality among patients with MS and its persistent correlation with fatigue and reduced quality of life over time. They highlight the importance of interventions to improve sleep quality.PubMedPubMedCentralCrossRef

53.

Aurora RN, Kristo DA, Bista SR, Rowley JA, Zak RS, Casey KR, et al. The treatment of restless legs syndrome and periodic limb movement disorder in adults--an update for 2012: practice parameters with an evidence-based systematic review and meta-analyses: an American Academy of Sleep Medicine Clinical Practice Guideline. Sleep. 2012;35(8):1039–62. https://doi.org/10.5665/sleep.1988.PubMedPubMedCentralCrossRef

54.

•• Hensen HA, Krishnan AV, Eckert DJ. Sleep-Disordered Breathing in People with Multiple Sclerosis: Prevalence, Pathophysiological Mechanisms, and Disease Consequences. Front Neurol. 2017;8:740. https://doi.org/10.3389/fneur.2017.00740 This review was aiming to shed light in the pathophysiological mechanisms that contribute to sleep disordered breathing in people with MS or whether MS contributes to SDB disease progression. The authors concluded that recent evidence indicate that treatment of SDB in people with MS with conventional first-line therapy, continuous positive airway pressure therapy, can reduce fatigue and cognitive impairment. PubMedCrossRef

55.

Sleep-related breathing disorders in adults: recommendations for syndrome definition and measurement techniques in clinical research. The Report of an American Academy of Sleep Medicine Task Force. Sleep. 1999;22(5):667–89.

56.

Braley TJ, Segal BM, Chervin RD. Obstructive sleep apnea and fatigue in patients with multiple sclerosis. J Clin Sleep Med. 2014;10(2):155–62. https://doi.org/10.5664/jcsm.3442.PubMedPubMedCentralCrossRef

57.

Kaminska M, Kimoff RJ, Benedetti A, Robinson A, Bar-Or A, Lapierre Y, et al. Obstructive sleep apnea is associated with fatigue in multiple sclerosis. Mult Scler. 2012;18(8):1159–69. https://doi.org/10.1177/1352458511432328.PubMedCrossRef

58.

Edwards BA, Eckert DJ, Jordan AS. Obstructive sleep apnoea pathogenesis from mild to severe: is it all the same? Respirology. 2017;22(1):33–42. https://doi.org/10.1111/resp.12913.PubMedCrossRef

59.

Dempsey JA, Veasey SC, Morgan BJ, O'Donnell CP. Pathophysiology of sleep apnea. Physiol Rev. 2010;90(1):47–112. https://doi.org/10.1152/physrev.00043.2008.PubMedPubMedCentralCrossRef

60.

Chotinaiwattarakul W, O'Brien LM, Fan L, Chervin RD. Fatigue, tiredness, and lack of energy improve with treatment for OSA. J Clin Sleep Med. 2009;5(3):222–7.PubMedPubMedCentral

61.

Rong ZH, Li WB, Liu W, Cai BH, Wang J, Yang M, et al. Nasal bi-level positive airway pressure (BiPAP) versus nasal continuous positive airway pressure (CPAP) in preterm infants </=32 weeks: a retrospective cohort study. J Paediatr Child Health. 2016;52(5):493–8. https://doi.org/10.1111/jpc.13175.PubMedCrossRef

62.

Najafi MR, Toghianifar N, Etemadifar M, Haghighi S, Maghzi AH, Akbari M. Circadian rhythm sleep disorders in patients with multiple sclerosis and its association with fatigue: a case-control study. Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences. 2013;18(Suppl 1):S71–3.

63.

Lunde HM, Bjorvatn B, Myhr KM, Bo L. Clinical assessment and management of sleep disorders in multiple sclerosis: a literature review. Acta Neurol Scand Suppl. 2013;196:24–30. https://doi.org/10.1111/ane.12046.CrossRef

64.

Taphoorn MJ, van Someren E, Snoek FJ, Strijers RL, Swaab DF, Visscher F, et al. Fatigue, sleep disturbances and circadian rhythm in multiple sclerosis. J Neurol. 1993;240(7):446–8.PubMedCrossRef

65.

Ferini-Strambi L, Filippi M, Martinelli V, Oldani A, Rovaris M, Zucconi M, et al. Nocturnal sleep study in multiple sclerosis: correlations with clinical and brain magnetic resonance imaging findings. J Neurol Sci. 1994;125(2):194–7.PubMedCrossRef

66.

Wen J, Ariyannur PS, Ribeiro R, Tanaka M, Moffett JR, Kirmani BF, et al. Efficacy of N-acetylserotonin and melatonin in the EAE model of multiple sclerosis. J NeuroImmune Pharmacol. 2016;11(4):763–73. https://doi.org/10.1007/s11481-016-9702-9.PubMedCrossRef

67.

Tachibana N, Howard RS, Hirsch NP, Miller DH, Moseley IF, Fish D. Sleep problems in multiple sclerosis. Eur Neurol. 1994;34(6):320–3. https://doi.org/10.1159/000117070.PubMedCrossRef

68.

Sikes EM, Motl RW, Ness JM. Pediatric multiple sclerosis: current perspectives on health behaviors. Pediatric Health Med Ther. 2018;9:17–25. https://doi.org/10.2147/PHMT.S140765.PubMedPubMedCentralCrossRef

69.

Grover SA, Aubert-Broche B, Fetco D, Collins DL, Arnold DL, Finlayson M, et al. Lower physical activity is associated with higher disease burden in pediatric multiple sclerosis. Neurology. 2015;85(19):1663–9. https://doi.org/10.1212/WNL.0000000000001939.PubMedPubMedCentralCrossRef

70.

Grover SA, Sawicki CP, Kinnett-Hopkins D, Finlayson M, Schneiderman JE, Banwell B, et al. Physical activity and its correlates in youth with multiple sclerosis. J Pediatr. 2016;179:197–203 e2. https://doi.org/10.1016/j.jpeds.2016.08.104.PubMedCrossRef

71.

Zafar AB, Ness J, Dowdy S, Avis K, Bashir K. Examining sleep, fatigue, and daytime sleepiness in pediatric multiple sclerosis patients. Mult Scler. 2012;18(4):481–8. https://doi.org/10.1177/1352458511424307.PubMedCrossRef

Titel: Sleep Abnormalities in Multiple Sclerosis
verfasst von: Giorgos K. Sakkas, PhD
Christoforos D. Giannaki, PhD
Christina Karatzaferi, PhD
Mauro Manconi, MD, PhD
Publikationsdatum: 01.01.2019
Verlag: Springer US
Erschienen in: Current Treatment Options in Neurology / Ausgabe 1/2019
Print ISSN: 1092-8480
Elektronische ISSN: 1534-3138
DOI: https://doi.org/10.1007/s11940-019-0544-7

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Purpose of review

Recent findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2019

Advances in Management of Psychosis in Neurodegenerative Diseases

Treatment and Outcomes in Nutritional Optic Neuropathy

Diagnostic Criteria, Differential Diagnosis, and Treatment of Minor Motor Activity and Less Well-Known Movement Disorders of Sleep